Non-Vascular Stents Market

Non-Vascular Stents Market Size, Market Forecast and Outlook By FMI

Summary of the Non-Vascular Stents Market

• Demand and Growth Drivers
  • Rising prevalence of gastrointestinal cancers, urological obstructions, and biliary strictures is increasing procedure volumes for non-vascular stent placements across hospitals and specialty clinics.
  • Growth in minimally invasive therapeutic approaches is shifting procedural preferences toward stent-based interventions that reduce hospital stays and recovery times compared to open surgical alternatives.
  • Advancement in biodegradable and drug-eluting stent platforms is expanding the clinical applicability of non-vascular stents beyond palliative care into curative treatment pathways.
• Product and Segment View
  • Ureteral stents are expected to hold 38.7% of the product type segment in 2026, shaped by growing demand for urological interventions related to kidney stones and ureteral strictures.
  • Non-metallic stents are expected to account for 52.2% of the material segment, supported by preference for biocompatible polymers and silicone-based designs in sensitive anatomical locations.
  • Hospitals remain the primary end-user channel, with centralized procurement of stent inventories for gastroenterology, urology, and pulmonology departments.
• Geography and Competitive Outlook
  • ANZ is expected to lead growth at 6.5% CAGR, supported by advanced healthcare infrastructure and high rates of endoscopic intervention adoption.
  • China and South Korea are each expected to grow at 6.0%, reflecting expanding hospital capacity and increasing access to advanced endoscopic and urological procedures.
  • Companies with broad product portfolios spanning multiple stent types and advanced material platforms are positioned to capture procurement preference across hospital networks.
• Analyst Opinion
  • The non-vascular stents market is evolving from a procedure-driven commodity category into a technology-differentiated segment where material science and delivery system design increasingly influence procurement decisions.
  • Adoption is increasing due to the shift toward outpatient and ambulatory surgical settings, which favors stent designs that simplify placement and reduce procedure times.
  • Companies that can demonstrate clinical superiority in reducing restenosis rates and migration complications while maintaining competitive pricing are likely to strengthen their market position over the forecast period.
  • Growth reflects the expanding scope of stent applications beyond traditional palliative care into curative and bridge-to-surgery indications, supported by evidence from multi-center clinical trials.

Key Takeaways, Market Size, and Forecast

• The non-vascular stents market was valued at USD 1.4 billion in 2025.
• The market is projected to reach USD 1.5 billion in 2026 and USD 2.4 billion by 2036, growing at a CAGR of 5.2%.
• By 2036, the non-vascular stents market is expected to be worth USD 2.45 billion.
• From 2026 to 2036, the market is projected to expand at a CAGR of 5.2%.
• The market is projected to create an incremental opportunity of USD 0.98 billion between 2026 and 2036.
• In 2026, Ureteral Stents are expected to account for 38.7% of the product type segment, driven by rising prevalence of urological conditions requiring minimally invasive interventions.
• Non-Metallic Stents are expected to lead the material type segment with a 52.2% share.
• ANZ (6.5%) and China (6.0%) are two of the fastest growing markets in the world.

Non-Vascular Stents Market Definition

The non-vascular stents market includes tubular devices designed for placement within non-vascular luminal structures to maintain patency, relieve obstructions, and support tissue integrity. Product categories include ureteral stents, biliary stents, esophageal stents, colonic stents, and bronchial stents, manufactured from metallic, non-metallic, and hybrid materials.

Non-Vascular Stents Market Inclusions

Market scope covers all commercially traded non-vascular stent products categorized by product type (ureteral stents, biliary stents, esophageal stents, colonic stents, bronchial stents), material (non-metallic stents, metal stents, hybrid stents), application (malignant obstructions, benign obstructions, palliative care), technology (self-expanding stents, balloon-expandable stents, drug-eluting stents, biodegradable-bioresorbable stents, anti-reflux stents), and end user (hospitals, specialty clinics, ambulatory surgical centers). Revenue coverage spans 2026 to 2036.

Non-Vascular Stents Market Exclusions

The scope does not include vascular stents (coronary, peripheral, or neurovascular), urethral catheters, or temporary drainage tubes that do not function as structural support devices.

Non-Vascular Stents Market Research Methodology

• Primary Research: FMI analysts conducted interviews with interventional gastroenterologists, urologists, pulmonologists, and hospital procurement teams across major healthcare markets.
• Desk Research: Combined data from medical device regulatory filings, clinical trial registries, and hospital procedure volume databases.
• Market sizing and forecasting: Bottom-up aggregation from procedure volumes across product types, clinical indications, and regions with adoption velocity projections.
• Data validation: Cross-checked quarterly against device registration databases and manufacturer shipment disclosures.

Why is the Non-Vascular Stents Market Growing?

• Rising incidence of gastrointestinal malignancies and biliary obstructions is increasing the clinical requirement for stent-based palliative and curative interventions across hospitals globally.
• The shift toward minimally invasive procedures is creating preference for stent placement over surgical resection in cases where clinical outcomes are comparable and recovery times are shorter.
• Advancement in biodegradable polymer platforms is expanding the clinical scope of non-vascular stents into temporary applications where stent removal carries procedural risk.

Non-vascular stent demand is shaped by the intersection of rising chronic disease burden and the clinical preference for less invasive therapeutic approaches. Ureteral stents account for the largest share of product demand, reflecting the high and growing incidence of kidney stones and urinary tract obstructions that require stent placement to maintain urinary flow. Biliary stents represent the second major product category, deployed primarily in cases of malignant biliary obstruction associated with pancreatic and bile duct cancers.

Material selection remains a key differentiator in procurement decisions. Non-metallic stents made from silicone, polyurethane, and biodegradable polymers hold over half the material segment, reflecting clinical preference for biocompatible designs that reduce tissue irritation and simplify removal. Metal stents, particularly self-expanding nitinol designs, are preferred in malignant obstructions where long-term patency and radial force are critical to maintaining luminal opening.

The competitive landscape is shaped by the ability to offer clinically differentiated products across multiple anatomical applications. Companies with portfolios spanning gastrointestinal, urological, and pulmonary stent categories can capture broader hospital procurement contracts. Drug-eluting and biodegradable platforms represent the next frontier of differentiation, with several products in late-stage clinical development that aim to reduce restenosis and eliminate the need for stent removal procedures.

Market Segmentation Analysis

• Ureteral stents hold 38.7% of the product type segment, with demand shaped by high procedure volumes in urological interventions for kidney stones and strictures.
• Non-metallic stents account for 52.2% of the material segment, reflecting clinical preference for biocompatible polymer and silicone designs in sensitive luminal applications.
• Hospitals account for the largest share of end-user demand, with centralized stent inventories serving gastroenterology, urology, and pulmonology departments.

The non-vascular stents market is segmented by product type, material, application, technology, and end user. Product types include ureteral stents, biliary stents, esophageal stents, colonic stents, and bronchial stents. Material categories span non-metallic stents, metal stents, and hybrid stents.

Insights into the Ureteral Stents Product Type Segment

In 2026, ureteral stents are expected to account for 38.7% of the product type segment. Demand is shaped by the high global incidence of kidney stones and ureteral strictures, which require stent placement to maintain urine flow and prevent renal damage. Double-J ureteral stents remain the most widely used design, with polymer-based constructions preferred for their flexibility and patient comfort.

Advancement in stent coatings that reduce bacterial adhesion and encrustation is addressing one of the primary complications associated with prolonged ureteral stent placement. Biodegradable ureteral stents that eliminate the need for a removal procedure are in clinical development and represent a significant growth opportunity.

Insights into the Non-Metallic Stents Material Segment

Non-metallic stents are expected to hold 52.2% of the material segment in 2026. Silicone and polyurethane remain the dominant materials for ureteral and biliary applications, offering flexibility, biocompatibility, and ease of insertion. The development of advanced polymer composites with enhanced radial strength is expanding the applicability of non-metallic designs into indications traditionally served by metal stents.

Biodegradable polymers represent the fastest-growing material subcategory, with clinical trials demonstrating feasibility in temporary stenting applications where the risk of a removal procedure outweighs the benefit.

Non-Vascular Stents Market Drivers, Restraints, and Opportunities

• Rising chronic disease burden and aging populations are increasing procedure volumes for stent-based interventions across gastroenterology, urology, and pulmonology.
• The higher cost of advanced stent platforms, including drug-eluting and biodegradable designs, limits adoption in price-sensitive healthcare systems with constrained reimbursement frameworks.
• The shift toward ambulatory surgical settings is creating demand for stent designs that simplify placement and reduce procedure times.

The non-vascular stents market is shaped by the convergence of rising disease burden, clinical preference for minimally invasive approaches, and material science innovation. While demographic and epidemiological trends support sustained volume growth, pricing pressure and reimbursement constraints in certain markets limit the commercial adoption of premium stent technologies.

Disease Burden and Procedure Volume Growth

Demand is shaped by rising global incidence of gastrointestinal cancers, biliary obstructions, kidney stones, and chronic respiratory conditions. As populations age and chronic disease prevalence increases, the clinical requirement for stent-based interventions grows correspondingly, creating a structural demand floor that is less sensitive to economic cycles than discretionary medical device purchases.

Reimbursement and Pricing Constraints

Adoption of premium stent technologies is constrained by reimbursement frameworks that do not differentiate between basic and advanced stent designs. In markets where procedure-based reimbursement covers a standard stent, hospitals have limited financial incentive to procure higher-cost drug-eluting or biodegradable alternatives, even when clinical outcomes may justify the additional cost.

Ambulatory and Outpatient Setting Expansion

Growth reflects the increasing proportion of stent procedures performed in ambulatory surgical centers and outpatient settings. Stent designs that enable faster placement, require less fluoroscopic guidance, and reduce post-procedural monitoring requirements are gaining traction as healthcare systems prioritize throughput and cost efficiency.

Biodegradable and Drug-Eluting Platform Development

Investment in next-generation stent platforms is creating opportunities for differentiation. Biodegradable stents that eliminate the need for removal procedures reduce both patient burden and healthcare resource utilization. Drug-eluting designs that reduce restenosis and tissue ingrowth are addressing the primary complication associated with long-term stent placement.

Analysis of Non-Vascular Stents Market By Key Countries

Country	CAGR
ANZ	6.5%
China	6.0%
South Korea	6.0%
Spain	5.7%
Germany	4.4%
France	3.8%
USA	3.2%

• ANZ leads growth at 6.5% CAGR, reflecting advanced endoscopic infrastructure and high adoption of minimally invasive urological and gastrointestinal procedures.
• China (6.0%) and South Korea (6.0%) are expanding rapidly, shaped by growing hospital capacity and increasing access to advanced endoscopic procedures.
• Spain at 5.7% shows strong demand supported by gastroenterology procedure volume growth and public health system investment in minimally invasive interventions.
• Germany at 4.4% reflects a mature market with established procurement channels and incremental growth from technology upgrades.

The global non-vascular stents market is expected to grow at 5.2% CAGR from 2026 to 2036. Demand varies by region based on disease burden, healthcare infrastructure maturity, and reimbursement frameworks.

Demand Outlook for Non-Vascular Stents Market in ANZ

ANZ is expected to grow at 6.5% through 2036, supported by advanced endoscopic infrastructure, high specialist density, and established clinical pathways for minimally invasive gastrointestinal and urological interventions.

• Advanced endoscopic infrastructure supports high procedure volumes.
• High specialist-to-population ratio enables rapid adoption of new stent technologies.
• Established clinical guidelines drive standardized stent procurement across hospital networks.

Future Outlook for Non-Vascular Stents Market in China

China is expected to grow at 6.0% through 2036, shaped by expanding hospital capacity, growing specialist training programs, and increasing access to advanced endoscopic and urological procedures across tier-2 and tier-3 cities.

• Hospital capacity expansion increases access to endoscopic procedures.
• Growing specialist training programs build clinical capability for stent placement.
• Domestic manufacturers are expanding product portfolios to compete with multinational suppliers.

Opportunity Analysis of Non-Vascular Stents Market in South Korea

South Korea is expected to grow at 6.0% through 2036, reflecting its advanced healthcare system, high adoption of minimally invasive techniques, and strong presence of domestic medical device manufacturers.

• Advanced healthcare system supports early adoption of next-generation stent designs.
• Strong domestic medical device manufacturing base enables competitive supply.
• High rates of endoscopic screening create downstream stent placement demand.

In-depth Analysis of Non-Vascular Stents Market in Spain

Spain is expected to grow at 5.7% through 2036, supported by gastroenterology procedure volume growth and public health system investment in endoscopic capabilities.

• Public health system procurement drives standardized stent utilization.
• Growing gastroenterology procedure volumes support biliary and esophageal stent demand.
• Aging population demographics increase the clinical need for palliative stenting.

Sales Analysis of Non-Vascular Stents Market in Germany

Germany is expected to grow at 4.4% through 2036, reflecting a mature market with established procurement channels and incremental growth driven by technology upgrades and clinical preference shifts toward advanced stent platforms.

• Mature healthcare infrastructure maintains steady replacement demand.
• Clinical preference shifts toward drug-eluting and biodegradable platforms.
• Strong regulatory framework ensures quality standards that favor established manufacturers.

In-depth Analysis of Non-Vascular Stents Market in the United States

The USA is expected to grow at 3.2% through 2036, reflecting a large installed base with moderate volume growth shaped by procedure mix shifts and incremental technology adoption.

• Large installed base maintains steady replacement and upgrade demand.
• Ambulatory surgical center expansion shifts procedure volumes from inpatient settings.
• Clinical preference for advanced stent materials supports premium product adoption.

Competitive Landscape and Strategic Positioning

• Boston Scientific Corporation leads the market with a broad non-vascular stent portfolio spanning biliary, esophageal, ureteral, and colonic applications.
• Becton, Dickinson and Company, Medtronic, and Cook Medical offer diversified product lines that cover multiple anatomical indications and material platforms.
• Specialized players like ELLA-CS and Micro-Tech (Nanjing) compete on specific product categories and regional distribution strength.

Boston Scientific Corporation holds a leading position through its broad portfolio of self-expanding and fully covered stent systems across gastrointestinal and urological applications. The company's investment in drug-eluting and anti-migration technologies differentiates its product line in hospital procurement evaluations.

Medtronic and Cook Medical compete with established product lines in biliary and esophageal stenting, leveraging their global distribution networks and clinical training programs. Becton, Dickinson and Company (BD) has strengthened its position through acquisitions that expanded its endoscopic device portfolio.

CONMED Corporation and ELLA-CS serve mid-market segments with competitive pricing and focused product offerings. Micro-Tech (Nanjing) is expanding internationally from a strong domestic base in China, offering a growing range of gastrointestinal stent products.

Barriers to entry include regulatory approval timelines for Class III medical devices, clinical trial requirements for new stent designs, and established group purchasing organization contracts that favor incumbent suppliers. Strategic priorities include expanding biodegradable and drug-eluting product lines and strengthening ambulatory surgical center distribution channels.

Key Companies in the Non-Vascular Stents Market

Key global companies leading the non-vascular stents market include:

• Boston Scientific Corporation (USA), Becton, Dickinson and Company (USA), Medtronic (Ireland), and Cook Medical (USA) are global leaders with comprehensive stent portfolios, established clinical evidence, and broad hospital distribution networks.
• CONMED Corporation (USA), ELLA-CS, s.r.o. (Czech Republic), and Glaukos Corporation (USA) are regional and specialty players with focused product lines targeting specific clinical indications and price-sensitive market segments.
• HOBBS MEDICAL, INC (USA), Micro-Tech (Nanjing) Co., Ltd. (China), and Merit Medical Systems (USA) are emerging competitors expanding their non-vascular stent offerings through technology development and international distribution partnerships.

Competitive Benchmarking: Non-Vascular Stents Market

Company	Product Portfolio Breadth	Clinical Evidence Base	Hospital Network Access	Geographic Reach
Boston Scientific	High	Strong	Strong	Global
BD	High	Strong	Strong	Global
Medtronic	High	Strong	Strong	Global
Cook Medical	High	Strong	Moderate	Global
CONMED Corporation	Medium	Moderate	Moderate	N. America, Europe
ELLA-CS	Medium	Moderate	Moderate	Europe
Glaukos Corporation	Low	Moderate	Moderate	N. America
HOBBS MEDICAL	Low	Low	Low	N. America
Micro-Tech (Nanjing)	Medium	Moderate	Moderate	Asia, Global
Merit Medical Systems	Medium	Moderate	Moderate	Global

Source: Future Market Insights competitive analysis, 2026.

Key Players in the Non-Vascular Stents Market

Major Global Players

• Boston Scientific Corporation
• Becton, Dickinson and Company (BD)
• Medtronic
• Cook Medical
• CONMED Corporation

Emerging Players/Startups

• ELLA-CS, s.r.o.
• Glaukos Corporation
• HOBBS MEDICAL, INC
• Micro-Tech (Nanjing) Co., Ltd.
• Merit Medical Systems

Report Scope and Coverage

Parameter	Details
Quantitative Units	USD 1.47 billion to USD 2.45 billion, at a CAGR of 5.2%
Market Definition	The non-vascular stents market encompasses tubular devices for placement within non-vascular luminal structures to maintain patency and relieve obstructions.
Regions Covered	North America, Latin America, Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, Germany, France, Spain, UK, China, South Korea, Japan, India, ANZ, 30 plus countries
Key Companies Profiled	Boston Scientific, BD, Medtronic, Cook Medical, CONMED, ELLA-CS, Glaukos, HOBBS MEDICAL, Micro-Tech (Nanjing), Merit Medical Systems
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down methodology starting with verified procedure volume data, projecting adoption across product types and regions.

Market Segmentation Analysis

Non-Vascular Stents Market Segmented by Product Type:

• Ureteral Stents
• Biliary Stents
• Esophageal Stents
• Colonic Stents
• Bronchial Stents

Non-Vascular Stents Market Segmented by Material:

• Non-Metallic Stents
• Metal Stents
• Hybrid Stents

Non-Vascular Stents Market Segmented by Application:

• Malignant Obstructions
• Benign Obstructions
• Palliative Care

Non-Vascular Stents Market Segmented by Technology:

• Self-Expanding Stents
• Balloon-Expandable Stents
• Drug-Eluting Stents
• Biodegradable-Bioresorbable Stents
• Anti-Reflux Stents

Non-Vascular Stents Market Segmented by End User:

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

Non-Vascular Stents Market by Region:

• North America
  • USA
  • Canada
  • Mexico
• Latin America
  • Brazil
  • Chile
  • Rest of Latin America
• Western Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • Nordic
  • BENELUX
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • Hungary
  • Balkan & Baltic
  • Rest of Eastern Europe
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia & New Zealand
  • Rest of South Asia and Pacific
• Middle East & Africa
  • Kingdom of Saudi Arabia
  • Other GCC Countries
  • Turkiye
  • South Africa
  • Other African Union
  • Rest of Middle East & Africa

Research Sources and Bibliography

• 1. World Health Organization. (2025). WHO Global Cancer Statistics: Incidence and Mortality Trends. WHO.
• 2. USA Food and Drug Administration. (2024). FDA Medical Device Classification: Non-Vascular Stent Guidance. FDA.
• 3. European Medicines Agency. (2024). EMA Medical Device Regulation: Clinical Evidence Requirements. EMA.
• 4. American Gastroenterological Association. (2025). AGA Clinical Guidelines: Endoscopic Stent Placement. AGA.
• 5. International Agency for Research on Cancer. (2025). IARC Globocan Database: Cancer Incidence Data. IARC.

This bibliography is provided for reader reference.

This Report Answers

• Estimating the market size and revenue projections from 2026 to 2036.
• Segmentation by product type, material, application, technology, and end user.
• Regional and country-level insights across more than 30 markets.
• Technology analysis covering self-expanding, balloon-expandable, drug-eluting, and biodegradable stent platforms.
• Assessment of the competitive landscape and strategic positioning.
• Identification of investment opportunities across gastroenterology, urology, and pulmonology applications.
• Supply chain and procurement trend tracking.
• Delivery of data in PDF and Excel formats.